Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sotera To Contact Him Directly To Discuss Their Options
New York, New York--(Newsfile Corp. - February 2, 2023) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sotera Health Company ("Sotera" or the "Company") (NASDAQ: SHC) and reminds investors of the March 27, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
If you suffered losses exceeding $100,000 investing in Sotera stock or options (i) pursuant and/or traceable to the Company's IPO conducted on or around November 20, 2020; (ii) pursuant and/or traceable to the Company's SPO conducted on or around March 18, 2021; and/or (iii) between November 20, 2020 and September 19, 2022, inclusive (the "Class Period") and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/SHC.
There is no cost or obligation to you.
Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
Sotera provides sterilization solutions, lab testing, and advisory services for the healthcare and pharmaceutical industries. Through its Sterigenics brand, Sotera provides sterilization services for the medical device and pharmaceutical markets. The Company uses Ethylene Oxide ("EtO") processing as one of three methods to sterilize products. EtO processing is a gas sterilization process in which pallets of packaged goods are loaded into a chamber that is then injected with EtO gas to penetrate the packaging. That process emits toxic fumes which must be filtered before being released into the air. Sotera, through its Sterigenics business, conducts or has conducted EtO processing at facilities throughout the United States, including Illinois, California, Georgia, and New Mexico, among other places.
Beginning in September 2018, cancer-stricken plaintiffs filed a surge of lawsuits in Illinois against Sotera, alleging that emissions from the Company's sterilization facility had caused their cancer. On September 30, 2019, after significant pressure from the public and action by Illinois regulators, Sotera announced the closure of its Illinois facility. Beginning in August 2020, cancer-stricken plaintiffs living near a Sterigenics facility in Georgia filed lawsuits similar to those filed in Illinois. Despite closing its Illinois facility and assuring investors and the public of the Company's purportedly effective safeguards to limit EtO emissions, Sotera continued to emit dangerous levels of EtO gas from other facilities during the Class Period.
The complaint alleges that, throughout the Class Period, and in connection with the IPO and the SPO, Sotera made false and misleading representations concerning its emissions control systems and exposure to liability from lawsuits for the Company's failure to limit harmful EtO emissions. The Company represented that it had "a proactive [environmental, health and safety] program and a culture of safety and quality." In addition, Sotera stated that it employed adequate and effective safeguards to control EtO emissions. Moreover, Sotera and its executives vehemently denied allegations that the Company's EtO emissions from its sterilization facilities caused cancer and other severe health issues in people living in the communities near those facilities.
In truth, however, Sotera and its senior executives and controlling shareholders knew, or at a minimum, recklessly disregarded, that for years the Company failed to employ effective emissions control systems to prevent the release of excessive amounts of toxic EtO gas from its sterilization facilities. Those deficiencies exposed people living in the surrounding communities to a significantly increased risk of cancer and subjected Sotera to an increased risk of liability from hundreds of EtO-related lawsuits. As a result of these misrepresentations, Sotera stock traded at artificially inflated prices throughout the Class Period.
The truth began to emerge on September 19, 2022, when a jury in the first lawsuit arising from Sotera's EtO emissions to go to trial, captioned Kamuda v. Sterigenics U.S., LLC, No. 18 L 10475 (Ill. Cir. Ct.) ("Kamuda"), found Sotera liable for the plaintiff's cancer. The jury cited Sotera's and Sterigenics' "willful and wanton" misconduct in not preventing toxic EtO emissions, and failing to warn about the severe health hazard posed by the Company's Illinois facility. As a result of these disclosures, Sotera's stock price declined by $4.90 per share, or 33.3%.
Later that day, after the market closed, news reports revealed that the jury verdict in the Kamuda case was supported by "[e]mails and corporate documents" that showed "the companies knew long ago" about the toxic effects of EtO. Despite that knowledge, Sotera "delayed installing pollution-control equipment and attempted to undermine federal regulations that would require costly improvements at sterilization facilities." The next day, on September 20, 2022, analysts at Goldman Sachs downgraded Sotera's stock, noting a significantly greater risk to Sotera in future EtO litigation due to facts that emerged in the Kamuda case and "possible bands of outcome being so open ended that it creates a material overhang on the stock for the foreseeable future." As a result of these disclosures, Sotera's stock price declined by an additional $1.63 per share, or 16.6%.
Then, on September 21, 2022, analysts at JP Morgan downgraded Sotera's stock after finding that "investors are likely to price in this unprecedented ruling as a higher probability of a larger settlement or subsequent payouts of the 700+ remaining individual lawsuits, which [Sotera] could potentially not afford." As a result of these disclosures, Sotera's stock price declined by an additional $0.88 per share, or 10.7%.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Sotera's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/153408
Original Source of the original story >> Sotera Shareholder Notice